0000000000359602

AUTHOR

Olivier Ganry

showing 4 related works from this author

Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Informatio…

2018

List of ACCIS contributors = Monika Hackl, Anna Zborovskaya, Nadya Dimitrova, Zdravka Valerianova, Ladislav Dušek, Margit Mägi, Alain Monnereau, Jacqueline Clavel, Michel Velten, Anne-Valérie Guizard, Véronique Bouvier, Xavier Troussard, Anne-Sophie Woronoff, Emilie Marrer, Brigitte Trétarre, Marc Colonna, Olivier Ganry, Pascale Grosclaude, Berndt Holleczek, Zsuzsanna Jakab, Laufey Tryggvadóttir, Lucia Mangone, Franco Merletti, Stefano Ferretti, Bianca Caruso, Maria Michiara, Rosario Tumino, Fabio Falcini, Roberto Zanetti, Giovanna Tagliabue, Otto Visser, Giske Ursin, Ryszard Mężyk, Kamila Kepska, José Laranja Pontes, Maja Primic Žakelj, Rafael Fernández-Delgado, Marisa L Vicente Raneda, En…

MaleCàncer en els infantsTime FactorsCancer in children0302 clinical medicineRisk FactorsNeoplasms030212 general & internal medicineRegistriesAge of OnsetChildmedia_commoneducation.field_of_studyCancer in adolescenceIncidence (epidemiology)Incidence3. Good healthEuropeOncology030220 oncology & carcinogenesisRegional studiesChild PreschoolFemale2730 OncologyAdolescentPopulationChildhood cancerSocio-culturale610 Medicine & healthRisk AssessmentArticle03 medical and health sciencesYoung AdultAge DistributionSDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansCàncer en els adolescentsEuropean unioneducationbusiness.industryInfant NewbornCancerInfantHealth Status Disparities10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseasePopulation based studyCancer incidencebusinessDemography
researchProduct

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCO…

2022

BACKGROUND Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during 2000-14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0-24 years). METHODS We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0-14 years), adolescents (15-19 years), and young adults (20-24 years). We categorised leukaemia subtypes a…

AdolescentAustralia610 Medicine & healthlymphomaSettore MED/42 - Igiene Generale E ApplicatasurvivalUnited StatesEuropeLeukemia Myeloid AcuteYoung Adultchildrenpopulation-based/cancer registry360 Social problems & social servicessurvival leukemia cancer registryHematologic NeoplasmsleukaemiaPediatrics Perinatology and Child HealthDevelopmental and Educational PsychologycancerHumansRegistrieshaematological malignancy610 Medicine & healthChild360 Social problems & social services
researchProduct

Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.

2015

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of diseases that are known to carry a considerable risk of second primary cancer (SPC). However, little attention has been paid to SPC risk assessment according to NHL subtypes. Data from 10 French population-based cancer registries were used to establish a cohort of 7546 patients with a first diagnosis of NHL (eight subtypes) between 1989 and 2004. Standardized incidence ratios (SIRs) of metachronous SPC were estimated. Among the 7546 patients diagnosed with a NHL, the overall SPC risk was 25% higher than that in the reference population (SIR = 1.25, 95% confidence interval 1.15–1.36). In univariate analysis, the SPC risk differed…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyanimal structuresMultivariate analysisAdolescentPopulationRisk AssessmentCohort StudiesYoung Adultimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiologymedicineHumansRegistrieseducationChildAgedAged 80 and overUnivariate analysiseducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinfungiAge FactorsInfant NewbornCancerInfantNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseOncologyChild PreschoolPopulation SurveillanceCohortImmunologyFemaleFranceRisk assessmentbusinessFollow-Up StudiesLeukemialymphoma
researchProduct

A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

2010

Summary Background Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions. The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers. Methods The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries. Data were collected using a standardized procedure. Results Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.…

MaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPerforation (oil well)Population[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaSampling Studies[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRegistries030212 general & internal medicineStage (cooking)educationAgedAged 80 and overPatient Care TeamChemotherapyeducation.field_of_studybusiness.industryAge FactorsGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgeryClinical trialChemotherapy AdjuvantIntestinal Perforation030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisPopulation studyFemaleFrancebusinessIntestinal Obstruction
researchProduct